Next 10 |
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capit...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. ...
2024-04-16 10:00:22 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...
2024-04-16 08:15:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for MRNS on April 16, 2024 06:31AM ET. The previous analyst recommendation was Overweight. MRNS was trading at $1.3 at issue of the analyst recommendation. The overall analyst consensus : H...
A look at the top 10 most actives in the United States PROSHARES TRUST (SQQQ) rose 5.1% to $11.44 on volume of 198,678,404 shares Trio Petroleum Corp. (TPET) rose 22.1% to $0.63 on volume of 179,140,668 shares Soligenix Inc. (SNGX) rose 21.7% to $0.47 on volume of 133,754,026 shares Sup...
2024-04-15 14:00:04 ET Sector Perform from RBC Capital issued a price target of $3.00 for MRNS on 2024-04-15 12:55:00. The adjusted price target was set to $3.00. At the time of the announcement, MRNS was trading at $1.415. The overall price target consensus is at $9.00 ...
2024-04-15 12:47:11 ET More on Mid-day movers & stocks. Enlivex stock plunges 50% on mixed results from sepsis study WiSA Technologies to effect 1-for-150 reverse stock split Seeking Alpha’s Quant Rating on BioSig Technologies, Inc. Historical earn...
2024-04-15 11:00:02 ET More on Marinus Pharmaceuticals Marinus Pharmaceuticals, Inc. (MRNS) Q4 2023 Earnings Call Transcript Marinus Pharmaceuticals Q4 2023 Earnings Preview Seeking Alpha’s Quant Rating on Marinus Pharmaceuticals Historical earnings da...
2024-04-15 10:00:31 ET More on Health Care Select Sector SPDR XLV: Fundamentals Don't Support Overweighting Health Care XLV: Low-Cost Exposure To A Defensive Sector, While Achieving Strong Performance Healthcare In 2024: Navigating The Biopharma Bull Run Shor...
A look at the top 10 most actives in the United States Soligenix Inc. (SNGX) rose 127.5% to $0.8782 on volume of 62,157,057 shares Trio Petroleum Corp. (TPET) rose 8.0% to $0.5571 on volume of 48,902,033 shares Organovo Holdings Inc. (ONVO) rose 36.3% to $1.3769 on volume of 34,819,187 sh...
News, Short Squeeze, Breakout and More Instantly...
Marinus Pharmaceuticals Inc. Company Name:
MRNS Stock Symbol:
NASDAQ Market:
Marinus Pharmaceuticals Inc. Website:
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein, M.D., Chairman and Chief Executive Officer, will be participating in a fireside chat at the RBC Capit...
Marinus Pharmaceuticals , Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that it plans to release financial results for the first quarter ended March 31, 2024 before market open on May 8, 2024. ...
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgr...